Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
01/25/2023 | Press release | Archived content
Please select the service you want to use:
Smartlinks | Esquire Financial Holdings Inc. | Finance | Security Markets | Security Markets | Company News | Top Company News | Corporate Debt | Financial Services | Banking | Securities Issuers | Banks | NYSE American | NYSE ARCA Equities | Nasdaq Capital Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact